Efficacy of N-Acetylcysteine in Prevention of Post-Catheterization Contrast-Induced Nephropathy in Diabetic Patients With Chronic Kidney Disease

• Status: Completed
• Trial end date: 2006-10-01

Summary

• Contrast-induced nephropathy (CIN) is the third most common cause of hospital acquired acute kidney injury, accounting for 10% of all cases.

• The pathophysiology of CIN is unclear. Possible mechanisms involve

1. Renal tubular injury by oxygen free radicals

2. Reducing renal blood flow which leads to acute tubular necrosis. Since N-acetylcysteine is an antioxidant as well as a vasodilator, it may work in two distinct ways, by preventing reduction in renal blood flow or contrast-induced oxidative damage.

• The purpose of this study is to evaluate the efficacy of N-acetylcysteine compared to placebo for the contrast-induced nephropathy prevention.

• Phase: Phase 3

Details

• Lead Sponsor: Tehran University of Medical Sciences
• Treatments: Acetylcysteine; N-monoacetylcystine